NCT06534463

Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

The Effectiveness and Safety of Different Treatment Modalities in Real-World Clinical Practice Among Chinese Patients with Marginal Zone Lymphoma: a Prospective, Observational, Multi-center Study

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.

Conditions

• Marginal Zone Lymphoma

Interventions

Type	Name	Description
OTHER	All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.	The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

Timeline

• Start date: 2024-08-02
• Primary completion: 2029-03-01
• Completion: 2029-09-01
• First posted: 2024-08-02
• Last updated: 2024-12-03

Locations

1 site across 1 country: China